Abstract
Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic virusesFuture cancer therapies will be molecular cures. They will correct, block or destroy cancer cells by targeting molecular changes that lead to carcinogenesis. Destroying cancer cells can be done using oncolytic viruses. By blocking antibody mediated neutralization of oncolytic viruses, Herpes simplex virus type 1 glycoproteins E and I could be used in the adjuvant treatment of cancer for improving the chances of oncolytic viruses to kill cancer cells in vivo.
Subject
Pharmaceutical Science,Pharmacology,General Medicine
Reference29 articles.
1. National Cancer Institute, Methods for Treatment and Their Side Effects http://www.nci.nih.gov/cancertopics/wyntk/overview/page15
2. Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines;T. Fischer;Int. J. Oncol,2006
3. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis;H. Brenner;Lancet,2001